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Abstract Controversy still exists about uric acid as a
potential prognosticrisk factor for outcomes in patients
with acute myocardial infarction. We prospectively asses-
sed, in 856 patients with ST-elevation myocardial infarc-
tion (STMI) consecutively admitted to our Intensive
Cardiac Care Unit after primary percutaneous coronary
intervention (PCI) whether uric acid (UA) levels are
associated with in-hospital mortality and complications.
Killip classes III-–IV were more frequent in the 3 UA
tertile that was associated with the highest values of peak
Tn I (p = 0.005), NT-proBNP (p \ 0.001), and fibrinogen
(p = 0.036). Uric acid was associated with mortality
(crude OR: 1.24; 95% CI 1.03–1.51; p = 0.025), but, when
adjusted for Tn I and renal failure (as inferred by eGFR
\60 ml/min/1.73 m2), uric acid lost its statistical signifi-
cance, while Tn I (100 pg/ml step OR: 1.002; 95% CI
1.000–1.003; p = 0.007) and renal failure (OR 9.16; 95%
CI 3.60–23.32; p \ 0.001) were independent predictors for
in-ICCU mortality. Uric acid remained as independent
predictor for in-ICCU complications (1 mg/dl step OR:
1.11; 95% CI 1.01–1.21; p = 0.030) together with admis-
sion glycemia (1 g/dl step OR: 1.50; 95% CI 1.19–1.91;
p \ 0.001) and renal failure (OR: 1.46; 95% CI 0.99–2.16;
p \ 0.001). In STEMI patients submitted to PCI, increased
uric acid levels identify a subgroup more prone to in-ICCU
complications, probably because hyperuricemia stems from
several complex mechanisms ranging from pre-existing
risk factors to the degree of myocardial ischemia
(as indicated by Killip class, ejection fraction) and to the
acute metabolic response (as inferred by glucose levels).
Hyperuricemia is not independently associated with early
mortality when adjusted for renal function and the degree
of myocardial damage.
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Introduction
In humans, uric acid (UA) is the end product of purine
catabolism [1]. Its serum levels, governed by the produc-
tion (liver) and elimination (mainly the kidney) rates, are
influenced by several variables, such as genetically deter-
mined factors (i.e., activity of synthesizing enzymes or
renal transport systems), racial and demographic charac-
teristics (i.e., gender), and morbidity (i.e., renal failure,
malignancies) [2].
The role of UA in cardiovascular and renal disease has
been intensively investigated, although not without con-
troversy [3, 4]. Over recent years, there has been renewed
debate concerning the nature of the association between
raised serum UA concentrations and cardiovascular disease
(CVD), and controversy still exists on whether hyperuri-
cemia is simply a risk marker (due to its strong association
with cardiovascular risk factors), or an independent risk
factor for atherosclerosis [5]. In general population samples
at relatively low risk for CVD, UA is a very weak predictor
of cardiovascular morbidity and mortality, once the effect
of known con-founders is accounted for [6]. On the con-
trary, UA seems to be a significant independent predictor of
CVD in certain categories of patients at high cardiovas-
cular risk, such as diabetics [7], patients with stroke [8],
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heart failure [9], and angiographically proven coronary
artery disease [10].
Less is known about UA as a potential prognosticrisk
factor for outcomes in patients affected specifically by acute
myocardial infarction [11–15], and several studies suggest
that a higher UA is independently associated with poorer
survival in these patients. However, studies on this topic
differ in number size, time of UA measurement (early phase
vs within the first 48 h), and type of reperfusion [throm-
bolysis vs. percutaneous coronary intervention (PCI)].
We prospectively assessed in 856 STEMI patients con-
secutively admitted to our Intensive Cardiac Care Unit
(ICCU) after primary PCI, whether UA levels are associ-
ated with in-ICCU mortality and complications.
Methods
Study population
From 1st January 2005 to 31st December 2009, 856 con-
secutive patients with STEMI (within 12 h from symp-
toms’ onset) were admitted to our Intensive Cardiac Care
Unit (ICCU), which is located at a tertiary center.
In our hospital, in Florence, the reperfusion strategy of
STEMI patients is represented by primary PCI [16–19].
Patients are first evaluated by the Medical Emergency
System staff in the pre-hospital setting and then directly
admitted to the catheterization laboratory or transferred to
it after a rapid stabilization in the Emergency Department
(ED). After primary PCI, they are admitted to our ICCU.
A successful procedure was defined as an infarct artery
stenosis \20% associated with TIMI (Thrombolysis in
Myocardial Infarction) grade 3 flow. Failure PCI was
defined as resulting in TIMI grade 0–2 flow, regardless of
the degree of residual stenosis [16].
The diagnosis of STEMI was based on the criteria of the
American College of Cardiology/American Heart Associ-
ation [17].
On ICCU admission, after PCI, in a fasting blood
sample the following parameters were measured: glucose
(g/l), troponin I (ng/ml), uric acid (mg/dl) [14], NT-pro
Brain Natriuretic Peptide (NT-BNP) (pg/ml) [14], leuko-
cyte count (9103/ll), fibrinogen (mg/dl), erythrocyte sed-
imentation rate (ESR), glycated hemoglobin (%),
cholesterol (mg/dl) and triglycerides (mg/dl). Creatinine
(mg/dl) was also measured in order to calculate glomerular
filtration rate (ml/min/1.73 m2). Glucose values and Tn I
were measured three times a day, and peak glucose and
peak Tn I were considered [20], respectively.
Transthoracic two-dimensional echocardiography was
performed on ICCU admission in order to measure left
ventricular ejection fraction (LVEF).
In-ICCU mortality and in-ICCU complications were
recorded. [21].
The study was approved by an appropriate ethics
committee, and all patients gave informed consent to
participate.
Statistical analysis
Data have been processed by means of SPSS 13.0 statis-
tical package (SPSS Inc, Chicago, IL, USA). A p value
\0.05 was considered statistically significant. Data are
reported as frequencies (percentages) and medians [95%
Confidence interval (CI)] and analyzed by means of v2 (or
Fisher’s exact text, when appropriate) and Mann–Whitney
U test, respectively. Moreover, study population has been
divided by tertiles of uric acid levels in order to investigate
which variables differed between the three subgroups.
Logistic regression analysis was carried out considering as
outcomes intra-ICCU mortality and complications. In these
two multivariable analyses, candidate variables were cho-
sen as those that demonstrated significantly differences at
univariable analysis or were clinically relevant. Backward
procedure (probability for entry: 0.05; probability for
removal: 0.10) was repeated until all variables in the model
reached statistical significance.
Results
Table 1 depicts the clinical characteristics of the 856
consecutive STEMI patients included in the study. In more
than half of the cases (54.2%) the acute myocardial
infarction was anterior. The incidence of PCI failure was
5.4%. In-ICCU mortality rate was 3.3% (28/856) while in-
ICCU complications were detected in the 28.0% (240/856).
Tertiles of uric acid (UA tertile) are shown in Table 2.
STEMI patients in the third UA tertile were the oldest
(p \ 0.001) and showed the highest BMI (p \ 0.001) and
triglyceride values (p \ 0.001) and the lowest eGFR
(p \ 0.001) and EF (p \ 0.001). Killip classes III–IV were
more frequent in the third UA tertile that was associated
with the highest values of peak Tn I (p = 0.005), NT-
proBNP (p \ 0.001), and fibrinogen (p = 0.036). Admis-
sion glucose and peak glycemia showed a progressive
significant increase among UA tertiles (p = 0.006 and
p \ 0.001, respectively). The incidence of in-ICCU com-
plications was significantly higher in the third UA tertile
while in-ICCU mortality rate did not show statistical dif-
ferences among UA tertiles.
When evaluating UA values on the basis of gender-
specific tertiles (Table 3), it was observed that in the first
tertile men showed higher values of uric acid, while in the
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second and third tertiles no gender-related differences in
uric acid values were observed.
Logistic regression analysis
Uric acid (considered as continuous variable) was associ-
ated with mortality (1 mg/dl step crude OR: 1.24; 95% CI
1.03–1.51; p = 0.025). When adjusted for Tn I and renal
failure (as inferred by eGFR \ 60 ml/min/1.73 m2), uric
acid lost its statistical significance (uric acid 1 mg/dl step:
OR: 1.02; 95% CI 0.83–1.26; p = 0.858), while Tn I
(100 pg/ml step OR: 1.002; 95% CI 1.000–1.003;
p = 0.007) and renal failure (OR 9.16; 95% CI 3.60–23.32;
p \ 0.001) were independent predictors for in-ICCU mor-
tality: Hosmer–Lemershow goodness-of-fit v2 = 5.889;
p = 0.660 (Table 4).
Uric acid was associated with in-hospital complications
(1 mg/dl step crude OR: 1.16; 95% CI 1.07–1.26;
p \ 0.001). At multivariable logistic regression analysis
uric acid remained as an independent predictor for in-ICCU
complications (1 mg/dl step OR: 1.11; 95% CI 1.01–1.21;
p = 0.030) together with admission glycemia (1 g/dl step
OR: 1.50; 95% CI 1.19–1.91; p \ 0.001) and renal failure
(OR: 1.46; 95% CI 0.99–2.16; p \ 0.001): Hosmer–Lem-
ershow goodness-of-fit v2 = 3.554; p = 0.895.
Discussion
The present investigation describes an independent asso-
ciation between higher UA levels and in-ICCU complica-
tions in a large series of consecutive STEMI patients
submitted to PCI.
Several factors may account for this finding. First, we
confirm the strong association between UA levels and
known cardiovascular risk factors, since UA values paral-
leled those of two of the components of the metabolic
syndrome (that is BMI and triglycerides) [1, 5, 6]. Second,
UA values appeared to be related to infarct size (as indi-
cated by peak Tn I), hemodynamic derangement
(as inferred by ejection fraction, Killip class and
NT-proBNP) as well as to the metabolic and inflammatory
acute responses to stress (as indicated by hyperglycemia
and fibrinogen values). Overall it can be speculated that, in
the early phase of STEMI patients, hyperuricemia stems
from several complex mechanisms, ranging from pre-
existing risk factors to the degree of myocardial ischemia,
and to the acute metabolic response. The underlying
mechanisms linking hyperuricemia to in-ICCU complica-
tions in the early phase of STEMI may be related to the
pro-oxydant [22] and pro-inflammatory actions [23]
attributed to uric acid and previously described in patients
with overt ischemic conditions [24, 25]. In experimental
models it is observed that, during tissue ischemia, the
enzymatic effect of xantine oxidase is the production of
reactive species of oxygen (ROS) and uric acid [25, 26];
hyperuricemia per se has been described to impair endo-
thelium-dependent vasodilatation by reduction NO-syn-
thase in animal experiments [27].
Previous studies investigated the relation between UA
levels and mortality in patients with acute myocardial
infarction, but the results are far from unanimous. Whereas
Homayounfar et al. [12] report that hyperuricemia is not an
independent prognostic risk factor for in-hospital death
Table 1 Clinical characteristics of patients with ST elevation myo-
cardial infarction included in the study
Median (25th–75th pct)
or frequency (%)
Age (years) 67.0 (58–76)
Males/females 643/213 (75.1/24.9%)
History of
Diabetes mellitus, n (%) 212 (24.8%)
Smoking, n (%) 537 (62.7%)
COPD, n (%) 73 (8.5%)
Previous PCI, n (%) 115 (13.4%)
Previous MI, n (%) 126 (14.7%)
Hypertension, n (%) 433 (50.6%)
Drugs on admission
ACE-inhibitors 774 (90,4%)
ARB 17 (2%)
Diuretics 102 (11.9%)
Estimated GFR (ml/min/1.73 m2) 78.4 (63.7–94.0)
AMI location
Anterior, n (%) 464 (54.2%)
Inferior, n (%) 328 (38.3%)
Other, n (%) 64 (7.5%)
Coronary artery disease
No disease, n (%) 2 (0.2%)
1-vessel, n (%) 331 (38.7%)
2-vessel, n (%) 297 (34.7%)
3-vessel, n (%) 226 (26.4%)
LM involvement, n (%) 63 (7.4%)
CABG involvement, n (%) 15 (1.8%)
PCI failure, n (%) 46 (5.4%)
Admission EF(%) 45.0 (35.0–50.0)
Latency (min) 240 (165–340)
In-hospital mortality, n (%) 28 (3.3%)
In-hospital complications, n (%) 240 (28.0%)
COPD chronic obstructive pulmonary disease, ACE angiotensin
converting enzyme, ARB angiotensin receptor blockers, PCI percu-
taneous coronary intervention, MI myocardial infarction, GFR glo-
merular filtration rate, AMI acute myocardial infarction, LN left main
coronary artery, CABG coronary artery bypass graft, EF ejection
fraction
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Table 2 Tertiles of uric acid in the study population
1 tertile
(B4.8 mg/dl;
n = 211)
2 tertile
(4.8–6.2 mg/dl;
n = 225)
3 tertile
([ 6.2 mg/dl;
n = 207)
p value
Age (years) Females 71.0 (61.0–78.0) 76.0 (62.0–82.0) 76.0 (68.0–82.0) 0.015
Males 62.0 (55.0–72.0) 65.0 (55.5–74.0) 68.0 (59.0–76.0) \0.001
p \0.001 \0.001 \0.001
BMI Females 24.0 (22.0–26.6) 25.4 (23.1–28.2) 26.0 (23.9–28.1) 0.007
Males 25.6 (23.5–27.0) 26.3 (24.6–28.4) 26.5 (24.4–28.7) \0.001
p 0.004 0.082 0.446
Estimated GFR (ml/min/1.73 m2) Females 75.0 (64.6–90.4) 71.8 (52.0–86.6) 56.0 (33.7–74.3) \0.001
Males 89.3 (77.1–104.3) 82.9 (71.3–95.9) 69.8 (49.7–86.2) \0.001
p \0.001 \0.001 \0.001
AMI anterior (%) Females 49 (56.3%) 36 (60.0%) 39 (59.1%) 0.892
Males 102 (48.6%) 116 (51.8%) 126 (58.5%) 0.028
p
Killip class
I-II Females 80 (91.9%) 53 (88.4%) 52 (78.6%) 0.054
Males 201 (95.3%) 203 (90.2%) 187 (85.5%) Females
III-IV Females 7 (8.1%) 7 (11.7%) 14 (21.4%) 0.006
Males 10 (4.7%) 22 (9.8%) 30 (14.5%) Males
p
EF (%) Females 45.0 (40.0–50.0) 40.0 (35.0–45.0) 40.0 (35.0–50.0) 0.007
Males 45.0 (39.0–53.0) 45.0 (38.0–50.8) 42.0 (35.0–50.0) 0.001
p 0.310 0.001 0.360
PCI failure Females (n = 213) 5 (5.7%) 7 (11.7%) 6 (9.1%) 0.436
Males (n = 635) 10 (4.7%) 9 (3.9%) 9 (4.3%) 0.927
p 0.774 0.051 0.211
Glucose (g/l) Females 1.38 (1.16–1.74) 1.47 (1.24–1.82) 1.52 (1.23–2.12) 0.073
Males 1.24 (1.07–1.62) 1.26 (1.09–1.56) 1.34 (1.14–1.78) 0.024
p 0.059 \0.001 0.017
Peak glucose (g/l) Females 1.60 (1.31–1.93) 1.73 (1.39–2.16) 2.04 (1.61–2.66) \0.001
Males 1.46 (1.24–1.86) 1.44 (1.22–1.78) 2.54 (1.32–2.08) 0.004
p 0.092 \0.001 \0.001
HbA1c (%) Females 6.1 (5.6–6.5) 6.0 (5.7–6.3) 6.1 (5.7–6.9) 0.266
Males 5.8 (5.5–6.5) 5.9 (5.6–6.3) 5.9 (5.6–6.4) 0.580
p 0.176 0.711 0.015
HbA1c [ 6.5% Females (n = 153) 13 (21.7%) 9 (21.4%) 31 17 (33.3%) 0.290
Males (n = 415) 30 (23.3%) (21.1%) 27 (19.4%) 0.745
p 0.808 0.962 0.044
Peak Tn I Females 60.6 (36.0–117.0) 112.0 (43.5–216.9) 91.0 (32.5–292.2) 0.018
Males 69.5 (32.9–143.4) 75.7 (39.1–168.5) 99.0 (33.1–208.0) 0.095
p 0.397 0.175 0.516
NT-proBNP Females 1306 (590–3230) 3664 (1738–6535) 4689 (1802–12708) \0.001
Males 844 (324–1662) 1234 (434–2408) 1686 (618–4071) 0.002
p 0.023 \0.001 \0.001
Uric acid Females 3.7 (3.2–4.2) 5.6 (5.3–5.8) 7.5 (6.7–8.5) \0.001
Males 4.2 (3.7–4.5) 5.6 (5.3–6.0) 7.3 (6.7–8.2) \0.001
p \0.001 0.756 0.283
Intern Emerg Med
123
after AMI, Kojima et al. [13] find that the total mortality
rate of patients whose serum UA concentrations are in the
highest quartile is about 3.7 times higher than in those
whose UA concentrations are in the lowest quartile. In their
retrospective study (the Japanese Acute Coronary Syn-
drome Study), the Authors conclude that serum UA is a
Table 3 UA analyis on the basis of sex specific tertiles
1tertile (B4.8 mg/dl; n = 211) 2 tertile (4.8–6.2 mg/dl; n = 225) 3 tertile ([6.2 mg/dl; n = 207) p value
Uric acid Females 3.7 (3.2–4.2) 5.6 (5.3–5.8) 7.5 (6.7–8.5) \0.001
Males 4.2 (3.7–4.5) 5.6 (5.3–6.0) 7.3 (6.7–8.2) \0.001
p \0.001 0.756 0.283
Comparisons have been performed with v2 or Fisher’s exact test for categorical variables and with Kruskal–Wallis (between tertiles of uric acid)
and Mann–Whitney U (between gender) for continuous variables
Table 2 continued
1 tertile
(B4.8 mg/dl;
n = 211)
2 tertile
(4.8–6.2 mg/dl;
n = 225)
3 tertile
([ 6.2 mg/dl;
n = 207)
p value
ESR Females 34 (20–46) 34 (22–50) 39 (18–56) 0.729
Males 20 (12–36) 24 (14–38) 26 (12–47) 0.235
p \0.001 0.001 0.020
Leucocytes (9103/ll) Females 10.2 (8.6–13.5) 12.5 (9.4–15.1) 11.0 (9.1–14.7) 0.076
Males 11.0 (9.0–13.6) 10.7 (8.7–14.1) 11.2 (9.2–14.4) 0.480
p 0.167 0.099 0.905
CRP positivity Females (n = 182) 37 (49.3%) 38 (71.7%) 36 (66.7%) 0.023
Males (n = 528) 91 (54.8%) 100 (52.6%) 100 (58.1%) 0.572
p 0.429 0.013 0.264
Fibrinogen Females 390 (354–470) 408 (344–493) 455 (354–521) 0.145
Males 368 (320–445) 382 (328–450) 393 (319–527) 0.149
p 0.015 0.118 0.055
Total cholesterol Females 198 (171–222) 187 (153–224) 185 (151–223) 0.610
Males 180 (154–204) 188 (159–210) 184 (148–210) 0.372
p 0.004 0.486 0.234
HDL cholesterol Females 46 (39–56) 46 (36–52) 42 (34–52) 0.091
Males 41 (35–49) 39 (34–44) 40 (33–47) 0.113
p \0.001 0.004 0.038
LDL cholesterol Females 127 (106–152) 122 (90–154) 115 (88–150) 0.428
Males 117 (96–140) 118 (98–144) 114 (92–140) 0.342
p 0.035 0.611 0.606
Triglycerides Females 81 (62–106) 93 (70–135) 111 (82–146) 0.001
Males 98 (68–130) 104 (82–145) 106 (81–147) 0.017
p 0.024 0.134 0.938
In-hospital complications Females 26 (29.9%) 22 (37.3%) 25 (38.5%) 0.479
Males 41 (19.5%) 60 (26.7%) 66 (32.3%) 0.013
p 0.054 0.118 0.365
In hospital mortality Females 0 6 (10.0%) 5 (7.4%) 0.015
Males 4 (1.9%) 6 (2.7%) 7 (3.4%) 0.639
p 0.326 0.022 0.170
Comparisons have been performed with v2 or Fisher’s exact test for categorical variables and with Kruskal–Wallis (between tertiles of uric acid)
and Mann–Whitney U (between gender) for continuous variables
BMI body mass index, GFR glomerular filtration rate, AMI acute myocardial infarction, EF ejection fraction, PCI percutaneous coronary
intervention, HbA1c glycosilated hemoglobin, Tn I troponin I, NT-proBNP N terminal-pro brain natriuretic peptide, ESR erythrocyte sedi-
mentation rate, CRP C-reactive protein, HDL high density lipoprotein, LDL low-density lipoprotein
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suitable marker for predicting AMI-related future. In their
investigation, patients (admitted from January to December
2002) were enrolled within 48 h after onset of symptoms,
and reperfusion was performed in 84% (mainly by means
of mechanical reperfusion). Our group [14] recently doc-
uments in a homogeneous population of 466 STEMI
patients all submitted to primary PCI within 12 h from
symptoms’ onset, that uric acid levels, measured after
mechanical revascularization on ICCU admission, is an
independent risk factor for in-hospital mortality. In the
present investigation, performed in a larger cohort of
STEMI patients, all submitted to mechanical revasculari-
zation, we failed to confirm the independent association
between uric acid and in-ICCU mortality, since when uric
acid was adjusted for eGFR and Tn I (that is renal function
and the extension of myocardial damage, respectively) it
was no longer associated with early mortality. Discrepan-
cies between the two studies can be related principally to
the different number of patients enrolled, since the studies
were performed in comparable STEMI populations.
In conclusion, in STEMI patients submitted to PCI,
increased uric acid levels identify a subgroup more prone
to in-ICCU complications, probably because hyperurice-
mia stems from several complex mechanisms ranging from
pre-existing risk factors to the degree of myocardial
ischemia and to the acute metabolic response.
Hyperuricemia is not independently associated with early
mortality when adjusted for renal function and the degree
of myocardial damage.
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